Form 8-K - Current report:
SEC Accession No. 0001641172-25-000971
Filing Date
2025-03-27
Accepted
2025-03-27 17:15:25
Documents
16
Period of Report
2025-03-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40506
2 ex99-1.htm EX-99.1 22904
3 ex99-1_001.jpg GRAPHIC 9585
  Complete submission text file 0001641172-25-000971.txt   299327

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20250327.xsd EX-101.SCH 3785
5 XBRL DEFINITION FILE lixt-20250327_def.xml EX-101.DEF 26651
6 XBRL LABEL FILE lixt-20250327_lab.xml EX-101.LAB 36769
7 XBRL PRESENTATION FILE lixt-20250327_pre.xml EX-101.PRE 25275
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5794
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 25780519
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)